ERAS
Price
$2.86
Change
-$0.13 (-4.35%)
Updated
Sep 6 closing price
60 days until earnings call
ORIC
Price
$9.65
Change
+$0.17 (+1.79%)
Updated
Sep 6 closing price
58 days until earnings call
Ad is loading...

ERAS vs ORIC

Header iconERAS vs ORIC Comparison
Open Charts ERAS vs ORICBanner chart's image
Erasca
Price$2.86
Change-$0.13 (-4.35%)
Volume$2.53M
CapitalizationN/A
Oric Pharmaceuticals
Price$9.65
Change+$0.17 (+1.79%)
Volume$312.01K
CapitalizationN/A
View a ticker or compare two or three
ERAS vs ORIC Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORIC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ERAS vs. ORIC commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and ORIC is a Hold.

COMPARISON
Comparison
Sep 08, 2024
Stock price -- (ERAS: $2.97 vs. ORIC: $9.47)
Brand notoriety: ERAS and ORIC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 185% vs. ORIC: 36%
Market capitalization -- ERAS: $807.96M vs. ORIC: $680.73M
ERAS [@Biotechnology] is valued at $807.96M. ORIC’s [@Biotechnology] market capitalization is $680.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $584.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileORIC’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • ORIC’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than ORIC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 7 TA indicator(s) are bullish while ORIC’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 7 bullish, 3 bearish.
  • ORIC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than ORIC.

Price Growth

ERAS (@Biotechnology) experienced а +5.87% price change this week, while ORIC (@Biotechnology) price change was -7.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.71%. For the same industry, the average monthly price growth was +3.67%, and the average quarterly price growth was -3.87%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 06, 2024.

ORIC is expected to report earnings on Nov 04, 2024.

Industries' Descriptions

@Biotechnology (-2.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($808M) has a higher market cap than ORIC($681M). ERAS YTD gains are higher at: 39.671 vs. ORIC (2.935). ORIC has higher annual earnings (EBITDA): -124.06M vs. ERAS (-148.65M). ERAS has more cash in the bank: 408M vs. ORIC (286M). ORIC has less debt than ERAS: ORIC (2.77M) vs ERAS (54M). ERAS (0) and ORIC (0) have equivalent revenues.
ERASORICERAS / ORIC
Capitalization808M681M119%
EBITDA-148.65M-124.06M120%
Gain YTD39.6712.9351,352%
P/E RatioN/AN/A-
Revenue00-
Total Cash408M286M143%
Total Debt54M2.77M1,949%
TECHNICAL ANALYSIS
Technical Analysis
ERASORIC
RSI
ODDS (%)
Bullish Trend 3 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend about 1 month ago
86%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORIC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AINTX15.480.08
+0.52%
Ariel International Investor
PIIFX27.430.11
+0.40%
Pioneer International Equity A
VFSNX230.500.66
+0.29%
Vanguard FTSE All-Wld ex-US SmCp Idx Ins
ACWDX16.82N/A
N/A
AMG GW&K Small/Mid Cap Growth N
BHEIX29.30-0.12
-0.41%
BlackRock High Equity Income K

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+6.63%
XNCR - ERAS
50%
Loosely correlated
-1.86%
KYMR - ERAS
44%
Loosely correlated
+0.93%
ABOS - ERAS
43%
Loosely correlated
-5.00%
BEAM - ERAS
42%
Loosely correlated
+0.46%
ABCL - ERAS
42%
Loosely correlated
-3.57%
More

ORIC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with SVRA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORIC
1D Price
Change %
ORIC100%
-1.25%
SVRA - ORIC
42%
Loosely correlated
+2.95%
FULC - ORIC
42%
Loosely correlated
+4.73%
KYMR - ORIC
42%
Loosely correlated
+0.93%
DAWN - ORIC
41%
Loosely correlated
+4.39%
ACLX - ORIC
41%
Loosely correlated
+7.50%
More